Anika Therapeutics (NASDAQ:ANIK) Issues Earnings Results

Anika Therapeutics (NASDAQ:ANIK) announced its earnings results on Friday. The biotechnology company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.13), FiscalAI reports. Anika Therapeutics had a positive return on equity of 0.20% and a negative net margin of 3.14%. The company had revenue of $30.59 million for the quarter, compared to the consensus estimate of $29.44 million.

Here are the key takeaways from Anika Therapeutics’ conference call:

• Revenue rose 10% to $30.6 million, with commercial revenue up 17% to a record $14 million and OEM revenue up 5%. Integrity grew more than 30% year over year, while international OA pain management revenue increased 19%.
• Anika raised its 2026 total revenue growth outlook to 6%–10% from 5%–10% and its adjusted EBITDA margin outlook to 15%–17% from 13%–17%. The outlook reflects stronger expected OEM growth, partly offset by a lower commercial growth range amid slower summer elective procedures.
• Gross margin improved to 62% from 56% a year ago, and adjusted EBITDA increased to $5.1 million from $0.9 million. The company generated $8.4 million in quarterly operating cash and ended September with $45 million in cash.
• Anika signed a new 10-year Hyvisc distribution agreement that includes higher transfer pricing, royalties, increased minimum purchases, and $8 million in upfront and volume-based payments. The $4 million upfront payment is expected in the first quarter of 2027.
• The FDA notified Anika that the Hyalofast U.S. PMA is not approvable, primarily because of the clinical data submitted; the company is evaluating regulatory pathways and potential additional evidence requirements. Separately, Anika expects to submit the Cingal NDA before the end of 2027, following completion of bioequivalence-study enrollment and ongoing CMC work.

Anika Therapeutics Stock Performance

NASDAQ ANIK opened at $14.55 on Friday. The stock has a 50-day simple moving average of $20.38 and a 200 day simple moving average of $16.25. Anika Therapeutics has a twelve month low of $9.01 and a twelve month high of $22.88. The stock has a market capitalization of $194.68 million, a PE ratio of -111.91, a P/E/G ratio of 10.39 and a beta of 0.21.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ANIK. Zacks Research cut shares of Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. B. Riley Financial began coverage on shares of Anika Therapeutics in a report on Friday, September 18th. They set a “buy” rating and a $23.00 price objective for the company. Wall Street Zen upgraded shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anika Therapeutics in a report on Monday, September 21st. Finally, Barrington Research set a $21.00 target price on shares of Anika Therapeutics in a report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $22.00.

Key Headlines Impacting Anika Therapeutics

Here are the key news stories impacting Anika Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 10% year over year to $30.59 million, beating the cited analyst estimate of $29.44 million. Commercial-channel revenue grew 17%, with Integrity revenue up more than 30%. Anika Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Anika raised the lower end of its 2026 revenue guidance and increased its adjusted EBITDA outlook. It forecast revenue of $119.6 million to $124.1 million, a range that includes the $121.6 million consensus estimate. Anika Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company secured a new 10-year Hyvisc partnership with improved economics and reintroduced a Hyaff product for non-orthopedic original-equipment-manufacturer customers, offering potential longer-term commercial support. Anika Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Adjusted EPS was reported at $0.29, above Zacks’ $0.17 estimate, while the cited results also show a GAAP loss of $0.02 per share. Analyst estimates differ across reports, making the earnings comparison mixed. Anika Therapeutics Beats Q3 Earnings and Revenue Estimates
• Negative Sentiment: The GAAP loss and reported EPS misses against some analyst benchmarks may have weighed on sentiment, despite the revenue beat and stronger adjusted-EPS comparison. Anika Therapeutics GAAP EPS and Revenue Results

About Anika Therapeutics

Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid.

Anika’s orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid.